Literature DB >> 33387103

Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.

Maria G Detsika1, K Goudevenou2, A M Geurts3, H Gakiopoulou4, E Grapsa5, Elias A Lianos6.   

Abstract

Decay accelerating factor (DAF), a key complement activation control protein, is a 70 kDa membrane bound glycoprotein which controls extent of formation of the C3 and C5 convertases by accelerating their decay. Using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9) genome editing we generated a novel DAF deficient (Daf-/-) rat model. The present study describes the renal and extrarenal phenotype of this model and assesses renal response to complement-dependent injury induced by administration of a complement-fixing antibody (anti-Fx1A) against the glomerular epithelial cell (podocyte). Rats generated were healthy, viable and able to reproduce normally. Complete absence of DAF was documented in renal as well as extra-renal tissues at both protein and mRNA level compared to Daf+/+ rats. Renal histology in Daf-/- rats showed no differences regarding glomerular or tubulointerstitial pathology compared to Daf+/+ rats. Moreover, there was no difference in urine protein excretion (ratio of urine albumin to creatinine) or in serum creatinine and urea levels. In Daf-/- rats, proteinuria was significantly increased following binding of anti-Fx1A antibody to podocytes while increased C3b deposition was observed. The DAF knock-out rat model developed validates the role of this complement cascade regulator in immune-mediated podocyte injury. Given the increasing role of dysregulated complement activation in various forms of kidney disease and the fact that the rat is the preferred animal for renal pathophysiology studies, the rat DAF deficient model may serve as a useful tool to study the role of this complement activation regulator in complement-dependent forms of kidney injury.

Entities:  

Keywords:  Anti-Fx1A; CRISPR; Complement; Decay accelerating factor (DAF)

Mesh:

Substances:

Year:  2021        PMID: 33387103     DOI: 10.1007/s11248-020-00222-x

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  5 in total

1.  Effect of nephritogenic antibody on complement regulation in cultured rat glomerular epithelial cells.

Authors:  R J Quigg; A V Cybulsky; D J Salant
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

2.  Decay accelerating factor regulates complement activation on glomerular epithelial cells.

Authors:  R J Quigg; A Nicholson-Weller; A V Cybulsky; J Badalamenti; D J Salant
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

Review 3.  The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy.

Authors:  Jan-Henrik Mikesch; Kathrin Schier; Antje Roetger; Ronald Simon; Horst Buerger; Burkhard Brandt
Journal:  Cell Oncol       Date:  2006       Impact factor: 6.730

4.  Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms.

Authors:  A P Spicer; M F Seldin; S J Gendler
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

Review 5.  The Heymann nephritis antigenic complex: megalin (gp330) and RAP.

Authors:  M G Farquhar; A Saito; D Kerjaschki; R A Orlando
Journal:  J Am Soc Nephrol       Date:  1995-07       Impact factor: 10.121

  5 in total
  1 in total

Review 1.  Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.

Authors:  Maria G Detsika; Elias A Lianos
Journal:  Antioxidants (Basel)       Date:  2021-01-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.